Inmaculada Ruiz-Montesinos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Inmaculada Ruiz-Montesinos has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Adolfo Beguiristain
4 shared publicationsFrancisco Garnateo
4 shared publicationsMiguel Echenique Elizondo
4 shared publicationsFrancisco Villar
3 shared publicationsMiguel A. Medrano
3 shared publicationsAdolfo Beguiristain Gómez
2 shared publications
Latest Publications
- Open Access
- 27 December 2025
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 43 (1) , 5
Impact of neoadjuvant cetuximab on liver function and tumor reduction in a murine model of selective portal vein ligation
Colorectal cancer mortality is largely driven by metastatic spread, with colorectal liver metastases (CRLM) being the most frequent. Treatment often combines surgery and systemic therapy, including anti-EGFR agents such as cetuximab. This study evaluated the cytoreductive effect of cetuximab on CRLM and its influence on liver function and regeneration in a selective portal vein ligation (PVL) model. Sixty-six male WAG/RijHsd rats were used. Seven days before PVL, twelve tumor-bearing animals received intra-arterial cetuximab, while other six received vehicle (saline). Additional groups included tumor-bearing rats without PVL, rats undergoing PVL alone, and untreated controls (n = 6 each). Seven days after PVL, the future remnant liver volume (%FRL) and hepatocyte replication were quantified. Serum markers for hepatic, renal, and systemic injury were analyzed, and tumor volume was assessed by ultrasound before and after PVL. The regenerative response following PVL was not significantly affected by cetuximab, with %FRL reaching 80–90%. However, hepatocyte nuclei exhibited a smaller mean area compared with non-treated animals (45.35 ± 9.09 vs. 43.54 ± 9.87 μm²; p < 0.001). Liver function remained preserved, although glucose levels decreased after PVL. Cetuximab significantly reduced tumor growth driven by hepatic regeneration (1.12 ± 0.45 vs. 0.53 ± 0.16 mL; p < 0.01). Neoadjuvant intra-arterial cetuximab does not impair liver regeneration after PVL while effectively limiting tumor proliferation linked to regenerative stimuli. These findings support its perioperative safety and potential use to prevent tumor recurrence in patients with CRLM undergoing staged hepatectomy.
- 27 December 2025
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 43 (1) , 5
Open AccessImpact of neoadjuvant cetuximab on liver function and tumor reduction in a murine model of selective portal vein ligation
Colorectal cancer mortality is largely driven by metastatic spread, with colorectal liver metastases (CRLM) being the most frequent. Treatment often combines surgery and systemic therapy, including anti-EGFR agents such as cetuximab. This study evaluated the cytoreductive effect of cetuximab on CRLM and its influence on liver function and regeneration in a selective portal vein ligation (PVL) model. Sixty-six male WAG/RijHsd rats were used. Seven days before PVL, twelve tumor-bearing animals received intra-arterial cetuximab, while other six received vehicle (saline). Additional groups included tumor-bearing rats without PVL, rats undergoing PVL alone, and untreated controls (n = 6 each). Seven days after PVL, the future remnant liver volume (%FRL) and hepatocyte replication were quantified. Serum markers for hepatic, renal, and systemic injury were analyzed, and tumor volume was assessed by ultrasound before and after PVL. The regenerative response following PVL was not significantly affected by cetuximab, with %FRL reaching 80–90%. However, hepatocyte nuclei exhibited a smaller mean area compared with non-treated animals (45.35 ± 9.09 vs. 43.54 ± 9.87 μm²; p < 0.001). Liver function remained preserved, although glucose levels decreased after PVL. Cetuximab significantly reduced tumor growth driven by hepatic regeneration (1.12 ± 0.45 vs. 0.53 ± 0.16 mL; p < 0.01). Neoadjuvant intra-arterial cetuximab does not impair liver regeneration after PVL while effectively limiting tumor proliferation linked to regenerative stimuli. These findings support its perioperative safety and potential use to prevent tumor recurrence in patients with CRLM undergoing staged hepatectomy.
- Open Access
- 28 March 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (7) , 761
Intrathecal Morphine in Major Abdominal and Thoracic Surgery: Observational Study
Introduction: Optimal control of acute postoperative pain after major surgery accelerates the recovery process, shortens hospital stays, and minimizes healthcare costs. Intrathecal morphine is a simple, safe, and reliable regional technique that provides prolonged analgesia, useful in a wide variety of procedures. Materials and Methods: A retrospective observational study was conducted on patients who underwent various major abdominal or thoracic surgical procedures and were administered intrathecal morphine between January 2018 and December 2021. The primary objective was to establish the safety of the technique in terms of the incidence of early and late respiratory depression, atelectasis, the need for respiratory support, and the possible association of these complications with the presence of respiratory pathologies such as chronic obstructive pulmonary disease (COPD) or sleep apnea–hypopnea syndrome (SAHS) and obesity or smoking habit. Secondary objectives included recording the consumption of rescue intravenous (IV) morphine in the first postoperative 24 h, the incidence of PONV, and the incidence of late postoperative complications (at 90 days) such as pneumonia, readmission rates, and reoperation rates. Hospital stay and mortality were also recorded. Results: A total of 484 patients were included in the study. No patient experienced respiratory depression. Atelectasis occurred in 2.07% of patients. Respiratory support with non-invasive mechanical ventilation (NIMV) or high-flow oxygen therapy (HFOT) was required by 1.86% of patients. In total, 51% of patients required rescue IV morphine (average 6.98 mg), with a rate significantly higher in the thoracic and general surgery groups compared to urological surgery. The incidence of postoperative nausea and vomiting (PONV) was 30.37%. Regarding other secondary objectives, readmissions, reoperations, and mortality rates were significantly higher in patients undergoing urological and thoracic surgery compared to those undergoing general surgery. Conclusions: The administration of intrathecal morphine for the control of acute postoperative pain after major surgery can be considered as a safe technique that fits perfectly within the set of measures for a multimodal approach to pain management in major abdominal and thoracic surgery.
- 28 March 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (7) , 761
Open AccessIntrathecal Morphine in Major Abdominal and Thoracic Surgery: Observational Study
Introduction: Optimal control of acute postoperative pain after major surgery accelerates the recovery process, shortens hospital stays, and minimizes healthcare costs. Intrathecal morphine is a simple, safe, and reliable regional technique that provides prolonged analgesia, useful in a wide variety of procedures. Materials and Methods: A retrospective observational study was conducted on patients who underwent various major abdominal or thoracic surgical procedures and were administered intrathecal morphine between January 2018 and December 2021. The primary objective was to establish the safety of the technique in terms of the incidence of early and late respiratory depression, atelectasis, the need for respiratory support, and the possible association of these complications with the presence of respiratory pathologies such as chronic obstructive pulmonary disease (COPD) or sleep apnea–hypopnea syndrome (SAHS) and obesity or smoking habit. Secondary objectives included recording the consumption of rescue intravenous (IV) morphine in the first postoperative 24 h, the incidence of PONV, and the incidence of late postoperative complications (at 90 days) such as pneumonia, readmission rates, and reoperation rates. Hospital stay and mortality were also recorded. Results: A total of 484 patients were included in the study. No patient experienced respiratory depression. Atelectasis occurred in 2.07% of patients. Respiratory support with non-invasive mechanical ventilation (NIMV) or high-flow oxygen therapy (HFOT) was required by 1.86% of patients. In total, 51% of patients required rescue IV morphine (average 6.98 mg), with a rate significantly higher in the thoracic and general surgery groups compared to urological surgery. The incidence of postoperative nausea and vomiting (PONV) was 30.37%. Regarding other secondary objectives, readmissions, reoperations, and mortality rates were significantly higher in patients undergoing urological and thoracic surgery compared to those undergoing general surgery. Conclusions: The administration of intrathecal morphine for the control of acute postoperative pain after major surgery can be considered as a safe technique that fits perfectly within the set of measures for a multimodal approach to pain management in major abdominal and thoracic surgery.
- Open Access
- 1 September 2023
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 16, 4141-4152
Prophylactic Treatment of Intestinal Ischemia-Reperfusion Injury Reduces Mucosal Damage and Improves Intestinal Absorption
Purpose: Intestinal ischemia-reperfusion injury (i–IRI) involves a blood flow interruption in an intestinal segment followed by blood flow restoration. When blood flow is restored, oxidative and inflammatory molecules are distributed throughout the bloodstream, triggering both local and systemic damage. Our goal was to evaluate the potential of three antioxidant and/or anti–inflammatory compounds (curcumin, dexmedetomidine and α-tocopherol) to prevent or reverse local and systemic damage induced by i–IRI. Methods: i-IRI was induced by placing a microvascular clip in the superior mesenteric artery of female WAG/RijHsd rats; the clip was removed after 1h and reperfusion was allowed for 4h. Curcumin (200 mg/kg, orally), α-tocopherol (20 mg/kg, i.p.), and dexmedetomidine (5 or 20 μg/kg, s.c.; DEX5 and DEX20, respectively) were administered. Blood and terminal ileum specimens were collected for biochemical and histological determination. Furthermore, D-xylose absorption test was performed to evaluate intestinal absorption; after completing the 1-hour ischemia and 4-hour reperfusion period, 1 mL of aqueous D-xylose solution (0.615 mg/mL) was administered orally, and one hour later, plasma D-xylose levels were quantified. Results: The histological injury degree (HID) measured by the Chiu scale was significantly reduced when the treatments were applied (non-treated rats, 2.6 ± 0.75; curcumin, 1.54 ± 0.8; DEX5, 1.47 ± 0.7; DEX20 1.14 ± 0.5; and α-tocopherol, 1.01 ± 0.6); intestinal absorptive capacity also improved in all cases healthy rats (2.06 ± 0.07 μg/mL; non-treated, 1.18 ± 0.07 μg/mL; curcumin 1.76 ± 0.3 μg/mL; DEX5, 2.29 ± 0.2 μg/mL; DEX20, 2.25 ± 0.26 μg/mL; and α-tocopherol 1.66 ± 0.21 μg/mL). However, it failed to reduce liver enzyme levels. Finally, only dexmedetomidine significantly reduced urea and creatinine levels compared to non-treated animals. Conclusion: All drugs were effective in reducing HID, although α-tocopherol was effective to a greater extent. Only dexmedetomidine reverted intestinal absorption to normal values of healthy animals.
- 1 September 2023
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 16, 4141-4152
Open AccessProphylactic Treatment of Intestinal Ischemia-Reperfusion Injury Reduces Mucosal Damage and Improves Intestinal Absorption
Purpose: Intestinal ischemia-reperfusion injury (i–IRI) involves a blood flow interruption in an intestinal segment followed by blood flow restoration. When blood flow is restored, oxidative and inflammatory molecules are distributed throughout the bloodstream, triggering both local and systemic damage. Our goal was to evaluate the potential of three antioxidant and/or anti–inflammatory compounds (curcumin, dexmedetomidine and α-tocopherol) to prevent or reverse local and systemic damage induced by i–IRI. Methods: i-IRI was induced by placing a microvascular clip in the superior mesenteric artery of female WAG/RijHsd rats; the clip was removed after 1h and reperfusion was allowed for 4h. Curcumin (200 mg/kg, orally), α-tocopherol (20 mg/kg, i.p.), and dexmedetomidine (5 or 20 μg/kg, s.c.; DEX5 and DEX20, respectively) were administered. Blood and terminal ileum specimens were collected for biochemical and histological determination. Furthermore, D-xylose absorption test was performed to evaluate intestinal absorption; after completing the 1-hour ischemia and 4-hour reperfusion period, 1 mL of aqueous D-xylose solution (0.615 mg/mL) was administered orally, and one hour later, plasma D-xylose levels were quantified. Results: The histological injury degree (HID) measured by the Chiu scale was significantly reduced when the treatments were applied (non-treated rats, 2.6 ± 0.75; curcumin, 1.54 ± 0.8; DEX5, 1.47 ± 0.7; DEX20 1.14 ± 0.5; and α-tocopherol, 1.01 ± 0.6); intestinal absorptive capacity also improved in all cases healthy rats (2.06 ± 0.07 μg/mL; non-treated, 1.18 ± 0.07 μg/mL; curcumin 1.76 ± 0.3 μg/mL; DEX5, 2.29 ± 0.2 μg/mL; DEX20, 2.25 ± 0.26 μg/mL; and α-tocopherol 1.66 ± 0.21 μg/mL). However, it failed to reduce liver enzyme levels. Finally, only dexmedetomidine significantly reduced urea and creatinine levels compared to non-treated animals. Conclusion: All drugs were effective in reducing HID, although α-tocopherol was effective to a greater extent. Only dexmedetomidine reverted intestinal absorption to normal values of healthy animals.
- 1 October 2014
- Published by Elsevier in Cirugía Española
- Vol. 92 (8) , 567-569
Neoplasia mucinosa quística de vesícula biliar con obstrucción intraluminal de colédoco, una entidad rara con un nuevo nombre
- 1 October 2014
- Published by Elsevier in Cirugía Española
- Vol. 92 (8) , 567-569
Neoplasia mucinosa quística de vesícula biliar con obstrucción intraluminal de colédoco, una entidad rara con un nuevo nombre
- 1 April 2013
- Published by Elsevier in Cirugía Española
- Vol. 91 (4) , 269-271
Duodenopancreatectomía cefálica con resección de vena mesentérica superior y reconstrucción mediante interposición de vena renal autóloga
- 1 April 2013
- Published by Elsevier in Cirugía Española
- Vol. 91 (4) , 269-271
Duodenopancreatectomía cefálica con resección de vena mesentérica superior y reconstrucción mediante interposición de vena renal autóloga
- 1 April 2011
- Published by Elsevier in Cirugía Española
- Vol. 89 (4) , 256-257
Dilatación biliar transparietohepática en paciente con intervención de Kasai
- 1 April 2011
- Published by Elsevier in Cirugía Española
- Vol. 89 (4) , 256-257
Dilatación biliar transparietohepática en paciente con intervención de Kasai
- 1 October 2008
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 31 (5) , 521-522
Intrahepatic Biliary Carcinoid
- 1 October 2008
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 31 (5) , 521-522
Intrahepatic Biliary Carcinoid
- 18 August 2008
- Published by American Medical Association (AMA) in Archives of Surgery
- Vol. 143 (8) , 805
Image of the Month—Quiz Case
Case Report from JAMA Surgery — Image of the Month—Quiz Case
- 18 August 2008
- Published by American Medical Association (AMA) in Archives of Surgery
- Vol. 143 (8) , 805
Image of the Month—Quiz Case
Case Report from JAMA Surgery — Image of the Month—Quiz Case
- 1 October 2007
- Published by Elsevier in Cirugía Española
- Vol. 82 (4) , 241-243
Hiperplasia nodular reactiva linfoidea hepática. Seudolinfoma
- 1 October 2007
- Published by Elsevier in Cirugía Española
- Vol. 82 (4) , 241-243
Hiperplasia nodular reactiva linfoidea hepática. Seudolinfoma
- Open Access
- 1 September 2006
- Published by Elsevier in Cirugía Española
- Vol. 80 (3) , 179
Carcinoide biliar intrahepático
- 1 September 2006
- Published by Elsevier in Cirugía Española
- Vol. 80 (3) , 179
Open AccessCarcinoide biliar intrahepático